Toggle Main Menu Toggle Search

Open Access padlockePrints

Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma

Lookup NU author(s): Dr Olivier GovaereORCiD



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2016 The Author(s).Background: Pancreatic cancer is poorly characterized at genetic and non-genetic levels. The current study evaluates in a large cohort of patients the prognostic relevance of molecular subtypes and key transcription factors in pancreatic ductal adenocarcinoma (PDAC). Methods: We performed gene expression analysis of whole-tumor tissue obtained from 118 surgically resected PDAC and 13 histologically normal pancreatic tissue samples. Cox regression models were used to study the effect on survival of molecular subtypes and 16 clinicopathological prognostic factors. In order to better understand the biology of PDAC we used iRegulon to identify transcription factors (TFs) as master regulators of PDAC and its subtypes. Results: We confirmed the PDAssign gene signature as classifier of PDAC in molecular subtypes with prognostic relevance. We found molecular subtypes, but not clinicopathological factors, as independent predictors of survival. Regulatory network analysis predicted that HNF1A/B are among thousand TFs the top enriched master regulators of the genes expressed in the normal pancreatic tissue compared to the PDAC regulatory network. On immunohistochemistry staining of PDAC samples, we observed low expression of HNF1B in well differentiated towards no expression in poorly differentiated PDAC samples. We predicted IRF/STAT, AP-1, and ETS-family members as key transcription factors in gene signatures downstream of mutated KRAS. Conclusions: PDAC can be classified in molecular subtypes that independently predict survival. HNF1A/B seem to be good candidates as master regulators of pancreatic differentiation, which at the protein level loses its expression in malignant ductal cells of the pancreas, suggesting its putative role as tumor suppressor in pancreatic cancer. Trial registration: The study was registered at under the number NCT01116791(May 3, 2010).

Publication metadata

Author(s): Janky R, Binda MM, Allemeersch J, Van den broeck A, Govaere O, Swinnen JV, Roskams T, Aerts S, Topal B

Publication type: Article

Publication status: Published

Journal: BMC Cancer

Year: 2016

Volume: 16

Pages: 1-15

Online publication date: 12/08/2016

Acceptance date: 08/07/2016

Date deposited: 08/12/2017

ISSN (electronic): 1471-2407

Publisher: BioMed Central Ltd


DOI: 10.1186/s12885-016-2540-6

PubMed id: 27520560


Altmetrics provided by Altmetric